Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:15:09 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



News for U:NTRA from 2023-05-03 to 2024-05-02 - 60 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-01 16:05U:NTRANews ReleaseNatera to Report its First Quarter 2024 Results on May 9
2024-05-01 07:00U:NTRANews ReleaseNatera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
2024-04-22 08:00U:NTRANews ReleaseNatera Announces Significant Milestone with 200+ Peer-Reviewed Publications
2024-04-11 08:00U:NTRANews ReleaseNatera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
2024-04-08 08:00U:NTRANews ReleaseNatera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera(TM) Heart dd-cfDNA Test for Heart Transplant Recipients
2024-04-05 07:00U:NTRANews ReleaseNatera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
2024-04-01 08:00U:NTRANews ReleaseNatera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
2024-03-18 07:00U:NTRANews ReleaseNatera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera(TM) in Stage II Colorectal Cancer
2024-03-14 08:00U:NTRANews ReleaseNew KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
2024-03-12 08:00U:NTRANews ReleaseNatera to Present New Data at the 2024 SGO Annual Meeting on Women's Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
2024-03-07 08:00U:NTRANews ReleaseNatera Announces Commercial Coverage for Prospera(TM) Kidney and Prospera Heart(TM) from a Top BCBS Plan
2024-02-29 08:00U:NTRANews ReleaseNatera to Participate in March Investor Conferences
2024-02-28 16:05U:NTRANews ReleaseNatera Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-27 08:00U:NTRANews ReleaseNatera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
2024-02-26 07:00U:NTRANews ReleaseMedicare Extends Coverage of Natera's Signatera(TM) MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
2024-02-20 08:00U:NTRANews ReleaseNatera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call
2024-02-05 08:00U:NTRANews ReleaseNew Study Validates Signatera ¢ „ ¢ in Endometrial Cancer
2024-01-30 09:15U:NTRANews ReleaseMultiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
2024-01-30 07:00U:NTRANews ReleaseNew Publication Demonstrates Signatera ¢ € ™s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
2024-01-29 07:00U:NTRANews ReleaseJury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
2024-01-25 07:00U:NTRANews ReleaseNature Medicine Publishes Two Studies Highlighting Signatera ¢ € ™s Clinical Utility in Patients with Gastrointestinal Malignancies
2024-01-22 07:00U:NTRANews ReleaseNatera Acquires Reproductive Health Assets from Invitae
2024-01-22 07:00U:NTRANews ReleaseInvitae Completes Sale of Reproductive Health Assets to Natera
2024-01-18 08:00U:NTRANews ReleaseNatera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera ¢ € ™s Clinical Utility in CRC
2024-01-16 17:17U:NTRANews ReleaseNatera Provides Update on Ravgen Trial
2024-01-09 07:00U:NTRANews ReleaseNatera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
2023-12-29 08:00U:NTRANews ReleaseNatera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-27 23:48U:NTRANews ReleaseNatera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics ¢ € ™ RaDaR Test
2023-12-11 12:50U:NTRANews ReleaseDelaware Court Denies CareDx ¢ € ™s Motion for Summary Judgment on Two Natera Patents
2023-12-06 08:30U:NTRANews ReleaseNatera Presents New Signatera ¢ „ ¢ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
2023-11-14 08:00U:NTRANews ReleaseNatera Announces Real-World Data Collaboration with Merck
2023-11-08 16:05U:NTRANews ReleaseNatera Reports Third Quarter 2023 Financial Results
2023-11-08 09:10U:NTRANews ReleaseNatera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
2023-11-07 08:30U:NTRANews ReleaseNatera to Participate in November Investor Conferences
2023-11-02 08:30U:NTRANews ReleaseNatera ¢ € ™s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight ¢ „ ¢ in Chronic Kidney Disease
2023-10-22 13:00U:NTRANews ReleaseUpdated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera ¢ € ™s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients
2023-10-20 09:00U:NTRANews ReleaseNatera to Report its Third Quarter 2023 Results on November 8
2023-10-19 09:00U:NTRANews ReleaseNatera Recognized on U.S. News & World Report ¢ € ™s 2024 Best Companies to Work for in Healthcare Ranking
2023-10-16 09:00U:NTRANews ReleaseNatera to Present New Signatera ¢ „ ¢ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study
2023-10-04 09:00U:NTRANews ReleaseNew MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera ¢ € ™s Ability to Risk Stratify and Detect Progression Early
2023-10-03 16:43U:NTRANews ReleaseSupreme Court Denies CareDx Request for Appeal in Patent Case with Natera
2023-10-02 09:00U:NTRANews ReleaseNatera Submits First PMA Module to the FDA for Signatera ¢ „ ¢
2023-09-18 09:00U:NTRANews ReleaseNatera Announces Senior Leadership Appointments
2023-09-14 09:00U:NTRANews ReleaseNatera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera ¢ „ ¢ for Breast Cancer Patients in the Neoadjuvant Setting
2023-09-07 00:09U:NTRANews ReleaseNatera Announces Pricing of $250 Million Follow-On Offering
2023-09-06 16:24U:NTRANews ReleaseNatera Launches Proposed Follow-On Offering
2023-09-01 09:00U:NTRANews ReleaseNatera to Participate in Upcoming Investor Conferences
2023-08-16 09:00U:NTRANews ReleaseNatera ¢ € ™s Prospera ¢ „ ¢ Lung Transplant Assessment Test Granted Medicare Coverage
2023-08-03 16:05U:NTRANews ReleaseNatera Reports Second Quarter 2023 Financial Results
2023-08-02 16:05U:NTRANews ReleaseNatera to Participate in Canaccord Genuity 43rd Annual Growth Conference
2023-07-31 13:39U:NTRANews ReleaseNatera Files Patent Infringement Suit Against NeoGenomics
2023-07-28 09:00U:NTRANews ReleaseNatera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera ¢ „ ¢ in Colorectal Cancer
2023-07-27 08:00U:NTRANews ReleaseNatera to Report its Second Quarter 2023 Results on August 3rd
2023-07-17 16:47U:NTRANews ReleaseCourt Issues Favorable Ruling for Natera in False Advertising Trial Against CareDx; Eliminates all Damages
2023-06-06 08:30U:NTRANews ReleaseNatera to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
2023-06-04 19:08U:NTRANews ReleaseNatera Announces Data from the ProActive Study that Supports Prospera ¢ „ ¢ Kidney as an Early Indicator of Transplant Rejection
2023-05-30 08:30U:NTRANews ReleaseNew Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types
2023-05-15 13:48U:NTRANews ReleaseJury Rules in Favor of Natera, Finding all Asserted Patents Valid and Infringed by ArcherDX/Invitae; Awards $19.35 Million in Past Damages for Royalties and Lost Profits
2023-05-09 16:05U:NTRANews ReleaseNatera Reports First Quarter 2023 Financial Results
2023-05-08 08:00U:NTRANews ReleaseNatera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera ¢ „ ¢ for Breast Cancer Patients in the Neoadjuvant Setting